Domestic political situation keeps German sales in check
This article was originally published in Clinica
German medical technology sales rose by 2% in 2005, an improvement on the 1.5% growth seen in 2004, but still far behind the international average, which, as in 2004, was 7%. So said industry association BVMed this week, reporting on the sales and profits of its 210 member companies. They seemed to perform marginally better in Germany than those of fellow industry association Spectaris, however; its member companies recorded a 2% drop in sales to the German market in 2005 (see Clinica No 1193, p 5).
You may also be interested in...
Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.
AstraZeneca's research head admits that the half dose approach was a lucky mistake - but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.
Alvotech has struck a major deal with Yangtze River Pharmaceutical that will allow eight of the biosimilars developer’s products to be commercialized in China.